CBLB and neoplasm: Interestingly, siRNA-mediated silencing of Cbl-B in CD8+ T-cells also improved the efficacy of dendritic cell-based tumor vaccines, indicating that inhibition of Cbl-B may become an adjuvant strategy to improve the efficacy of cancer immunotherapy (64–66).